ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s share price shot up 6.3% during mid-day trading on Thursday . The company traded as high as $2.59 and last traded at $2.54. 1,024,347 shares were traded during trading, a decline of 77% from the average session volume of 4,484,282 shares. The stock had previously closed at $2.39.
Analyst Ratings Changes
Several research firms have commented on IBRX. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a "strong-buy" rating in a research note on Wednesday, October 23rd. D. Boral Capital reissued a "buy" rating and set a $30.00 target price on shares of ImmunityBio in a research note on Thursday. Finally, BTIG Research initiated coverage on ImmunityBio in a report on Friday, January 10th. They set a "buy" rating and a $6.00 price target on the stock.
Get Our Latest Report on ImmunityBio
ImmunityBio Trading Down 3.3 %
The firm's fifty day simple moving average is $3.74 and its 200 day simple moving average is $4.25. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -3.20 and a beta of 0.86.
Hedge Funds Weigh In On ImmunityBio
Institutional investors and hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. lifted its holdings in ImmunityBio by 16.0% during the 2nd quarter. Victory Capital Management Inc. now owns 19,953 shares of the company's stock worth $126,000 after buying an additional 2,746 shares during the last quarter. Wealth Effects LLC raised its position in shares of ImmunityBio by 3.4% during the 3rd quarter. Wealth Effects LLC now owns 90,500 shares of the company's stock worth $337,000 after acquiring an additional 3,000 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in ImmunityBio by 8.4% during the third quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company's stock worth $178,000 after purchasing an additional 3,722 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in ImmunityBio by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock valued at $99,000 after purchasing an additional 4,545 shares in the last quarter. Finally, Courier Capital LLC increased its stake in ImmunityBio by 50.0% in the third quarter. Courier Capital LLC now owns 30,000 shares of the company's stock valued at $112,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Read More
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
